Physician profile

Daniela E Verani

Family Medicine · Londonderry, NH

NPI 1255431532

$1,302.44

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$166.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $751.38 2019-2024 Breztri, Farxiga, Airsupra
Kowa Pharmaceuticals America, INC. $154.76 2019-2021
Amarin Pharma, INC. $145.90 2020-2021
Janssen Pharmaceuticals, INC $115.47 2019-2021
Esperion Therapeutics, INC. $81.12 2021
Lilly USA, LLC $20.14 2021
Sanofi Pasteur INC. $19.47 2019
Idorsia Pharmaceuticals US INC $14.20 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniela E Verani

$1,302.44

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/456055/daniela-e-verani

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.